Yesintek, a Stelara biosimilar, received FDA approval for IBD, plaque psoriasis, and psoriatic arthritis, with a launch expected in late 2025. Clinical trials confirmed Yesintek's equivalence to ...
BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results